Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy

1. Hill, J. A. & Seo, S. K. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell

malignancies. Blood 136(8), 925–935 (2020).

2. Passweg, J. R. et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: Monitoring of activities and trends

over 30 years. Bone Marrow Transplant. 56(7), 1651–1664 (2021).

3. Lee, G. & Arepally, G. M. Anticoagulation techniques in apheresis: From heparin to citrate and beyond. J. Clin. Apher. 27(3),

117–125 (2012).

4. Buchta, C., Macher, M., Bieglmayer, C., Hocker, P. & Dettke, M. Reduction of adverse citrate reactions during autologous largevolume PBPC apheresis by continuous infusion of calcium-gluconate. Transfusion 43(11), 1615–1621 (2003).

5. Fujii, K. et al. Effectiveness of supplemental oral calcium drink in preventing citrate-related adverse effects in peripheral blood

progenitor cell collection. Transfus Apher. Sci. 60(4), 103147 (2021).

6. Hegde, V. et al. Prophylactic low dose continuous calcium infusion during peripheral blood stem cell (PBSC) collections to reduce

citrate related toxicity. Transfus Apher. Sci. 54(3), 373–376 (2016).

7. Kramer, L. et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit. Care Med.

31(10), 2450–2455 (2003).

8. Abdelmogheth, A. A., El-Baroudy, I. & Al-Yaaruby, S. Plasmapheresis-induced hypercalcaemia. Sultan Qaboos Univ. Med. J. 13(1),

147–151 (2013).

9. Nowak, M. A. & Campbell, T. E. Profound hypercalcemia in continuous veno-venous hemofiltration dialysis with trisodium citrate

anticoagulation and hepatic failure. Clin. Chem. 43(2), 412–413 (1997).

10. Warnar, C., Faber, E., Katinakis, P. A., Schermer, T. & Spronk, P. E. Electrolyte monitoring during regional citrate anticoagulation

in continuous renal replacement therapy. J. Clin. Monit. Comput. 36(3), 871–877 (2022).

11. Hematopoietic Cell Transplantation in Japan. Annual Report of Nationwide Survey 2021. In The Japanese Data Center for Hematopoietic Cell Transplantation/The Japanese Society for Transplantation and Cellular Therapy (2023).

12. Giralt, S. et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: Consensus guidelines and

recommendations. Biol. Blood Marrow Transplant. 20(3), 295–308 (2014).

13. Nadler, S. B., Hidalgo, J. H. & Bloch, T. Prediction of blood volume in normal human adults. Surgery 51(2), 224–232 (1962).

14. Matsuo, S. et al. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 53(6), 982–992 (2009).

15. Bilezikian, J. P. Clinical review 51: Management of hypercalcemia. J. Clin. Endocrinol. Metab. 77(6), 1445–1449 (1993).

16. Deftos, L. J. & First, B. P. Calcitonin as a drug. Ann. Intern. Med. 95(2), 192–197 (1981).

17. Bolan, C. D. et al. Randomized placebo-controlled study of oral calcium carbonate supplementation in plateletpheresis: II. Metabolic effects. Transfusion 43(10), 1414–1422 (2003).

18. Kishimoto, M. et al. Treatment for the decline of ionized calcium levels during peripheral blood progenitor cell harvesting. Transfusion 42(10), 1340–1347 (2002).

19. Schneider, A. G., Journois, D. & Rimmele, T. Complications of regional citrate anticoagulation: Accumulation or overload?. Crit.

Care. 21(1), 281 (2017).

Acknowledgements

We are grateful to Dr. Shinya Yamamoto (Department of Nephrology, Graduate School of Medicine, Kyoto

University) and Ms. Asuka Hada (Department of Human Health Sciences, Graduate School of Medicine, Kyoto

University) for helpful discussion, and to clinical engineers and nurses at the leukapheresis sites, transplant

coordinators, and all clinicians in Kyoto University Hospital for their support, as well as patients who contributed

to this research. This work was supported, in part, by the Program for Development of Next-generation Leading

Scientists with Global Insight (L-INSIGHT), sponsored by the Ministry of Education, Culture, Sports, Science

and Technology (MEXT), Japan to YA.

Author contributions

T.J. and Y.A. designed the study, reviewed, and analyzed data. T.J. and Y.A. wrote the paper; T.K., M.N., C.M.,

J.K., K.Y., M.N., and A.T.-K. interpreted data and revised the manuscript. All authors critiqued the manuscript.

Competing interests The authors declare no competing interests.

Scientific Reports |

(2023) 13:14952 |

https://doi.org/10.1038/s41598-023-42159-1

Vol.:(0123456789)

www.nature.com/scientificreports/

Additional information

Supplementary Information The online version contains supplementary material available at https://​doi.​org/​

10.​1038/​s41598-​023-​42159-1.

Correspondence and requests for materials should be addressed to Y.A.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and

institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International

License, which permits use, sharing, adaptation, distribution and reproduction in any medium or

format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the

Creative Commons licence, and indicate if changes were made. The images or other third party material in this

article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the

material. If material is not included in the article’s Creative Commons licence and your intended use is not

permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from

the copyright holder. To view a copy of this licence, visit http://​creat​iveco​mmons.​org/​licen​ses/​by/4.​0/.

© The Author(s) 2023

Scientific Reports |

Vol:.(1234567890)

(2023) 13:14952 |

https://doi.org/10.1038/s41598-023-42159-1

10

...